E2020 + Placebo
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Dementia, Lewy Body
Conditions
Dementia, Lewy Body, Lewy Body Disease
Trial Timeline
Mar 1, 2015 → Mar 26, 2018
NCT ID
NCT02345213About E2020 + Placebo
E2020 + Placebo is a approved stage product being developed by Eisai for Dementia, Lewy Body. The current trial status is completed. This product is registered under clinical trial identifier NCT02345213. Target conditions include Dementia, Lewy Body, Lewy Body Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02345213 | Approved | Completed |
| NCT01404169 | Phase 3 | Completed |
Competing Products
20 competing products in Dementia, Lewy Body
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| [18F]NAV4694 | Navidea Biopharmaceuticals | Phase 3 | 69 |
| AL001 + Placebo + Open label - AL001 | Alector | Phase 3 | 69 |
| AL001 | Alector | Phase 2 | 44 |
| ATH-1017 + Placebo | LeonaBio | Phase 2 | 44 |
| IGC AD1 + Placebo | IGC Pharma | Phase 1 | 25 |
| ARICEPT | Eisai | Phase 3 | 77 |
| Rasagiline | Eisai | Phase 2 | 52 |
| Donepezil Hydrochloride | Eisai | Pre-clinical | 23 |
| donepezil hcl | Eisai | Phase 3 | 77 |
| Donepezil 5 mg + Donepezil 10 mg + Donepezil matched placebo | Eisai | Phase 3 | 77 |
| E2020 + E2020 | Eisai | Phase 2 | 52 |
| donepezil hydrochloride (Aricept) | Eisai | Approved | 85 |
| 3 mg Donepezil hydrochloride + 5 mg Donepezil hydrochloride + 10 mg Donepezil hydrochloride + Placebo | Eisai | Phase 2 | 52 |
| E2020 + E2020 | Eisai | Phase 3 | 77 |
| Irsenontrine + Placebo | Eisai | Phase 2 | 52 |
| E2020 | Eisai | Phase 2 | 52 |
| Mecobalamin | Eisai | Approved | 85 |
| E2020 + Placebo | Eisai | Phase 3 | 77 |
| Donepezil Hydrochloride | Eisai | Phase 3 | 77 |
| Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochloride | Eisai | Approved | 85 |
Other Products from Eisai
MecobalaminApproved
85
MonteplaseApproved
85
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved
85
DonepezilApproved
85
Lemborexant (LEM) 5 mg (Z-Drug-mono cohort) + Lemborexant (LEM) 5 mg (SUV-mono cohort) + Lemborexant (LEM) 5 mg (SUV-combination cohort) + Lemborexant (LEM) 5 mg (RMT-combination cohort)Approved
85